tacrine has been researched along with Myasthenia Gravis in 3 studies
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Symptomatic treatment of myasthenia gravis is based on the use of peripherally-acting acetylcholinesterase (AChE) inhibitors that, in some cases, must be discontinued due to the occurrence of a number of side-effects." | 5.48 | Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis. ( Bartolini, M; Cieslikiewicz-Bouet, M; Clos, MV; Colletier, JP; Coquelle, N; Galdeano, C; Jean, L; Muñoz-Torrero, D; Pérez, B; Renard, PY; Silman, I, 2018) |
| "Symptomatic treatment of myasthenia gravis is based on the use of peripherally-acting acetylcholinesterase (AChE) inhibitors that, in some cases, must be discontinued due to the occurrence of a number of side-effects." | 1.48 | Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis. ( Bartolini, M; Cieslikiewicz-Bouet, M; Clos, MV; Colletier, JP; Coquelle, N; Galdeano, C; Jean, L; Muñoz-Torrero, D; Pérez, B; Renard, PY; Silman, I, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galdeano, C | 1 |
| Coquelle, N | 1 |
| Cieslikiewicz-Bouet, M | 1 |
| Bartolini, M | 1 |
| Pérez, B | 1 |
| Clos, MV | 1 |
| Silman, I | 1 |
| Jean, L | 1 |
| Colletier, JP | 1 |
| Renard, PY | 1 |
| Muñoz-Torrero, D | 1 |
| Kaur, J | 1 |
| Zhang, MQ | 1 |
| Jones, CR | 1 |
| Davis, M | 1 |
1 review available for tacrine and Myasthenia Gravis
| Article | Year |
|---|---|
Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Crystallography, X-Ray; Donepezil; Drug Des | 2000 |
2 other studies available for tacrine and Myasthenia Gravis
| Article | Year |
|---|---|
Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis.
Topics: Acetylcholinesterase; Aminoacridines; Aminoquinolines; Butyrylcholinesterase; Cholinesterase Inhibit | 2018 |
Letter: Replacement drug for edrophonium bromide.
Topics: Acridines; Adult; Cholinesterase Inhibitors; Edrophonium; Female; Humans; Myasthenia Gravis; Quatern | 1975 |